Melanotan I

01 · What it is

Melanotan I is a real medicine, and its approved purpose is the opposite of what the name is usually used to sell.

The compound is afamelanotide, marketed as SCENESSE — a synthetic analogue of α-melanocyte- stimulating hormone and the first-in-class melanocortin-1 receptor agonist ⁵. It is approved in the European Union for the prevention of phototoxicity in adults with erythropoietic protoporphyria ⁵, has been in clinical use there since 2016 ¹⁸, and was approved by the FDA in 2019 for erythropoietic protoporphyria-associated phototoxicity ¹³.

The indication is a rare disease in which people cannot tolerate daylight. Erythropoietic protoporphyria is an inherited disorder of heme biosynthesis in which accumulated protoporphyrin IX causes acute phototoxicity ¹⁰: tingling, burning, pain and itching within thirty minutes of sun or ultraviolet exposure, usually beginning in infancy or childhood ². Patients experience severe burning pain after light exposure and a markedly reduced quality of life ¹¹.

The drug works by making photoprotection possible. Its pivotal randomised evidence was published in the New England Journal of Medicine in 2015, reporting an acceptable side-effect and adverse-event profile and an association with increased duration of sun exposure ⁴.

Increased duration of sun exposure is the endpoint. For this population it means being able to go outside. A Dutch cohort found that 5% of patients were unemployed at baseline and none were unemployed during afamelanotide treatment ¹¹.

What this guide is careful about. Material sold as “Melanotan I” outside a pharmacy is not SCENESSE, has no established relationship to it, and the approved indication is a genetic photosensitivity disorder — not cosmetic pigmentation. The clinical literature cited here concerns a 16 mg controlled-release implant administered under specialist supervision ²⁰, which is a different product, a different route and a different setting from anything obtainable informally.

02 · Evidence at a glance

Evidence grade

Approved Pharma — EU and US approvals attested in the peer-reviewed literature ^5,13

Generic and brand name

Afamelanotide; SCENESSE. Also designated CUV1647 ³

Drug class

Synthetic α-MSH analogue; first-in-class MC1R agonist ⁵

Approved indication

Prevention of phototoxicity in adults with erythropoietic protoporphyria ^5,9

EU approval

Yes; in clinical application since 2016 ¹⁸

US approval

FDA, 2019 ¹³

Form studied

16 mg controlled-release implant ²⁰

Pivotal randomised evidence

New England Journal of Medicine, 2015 — acceptable safety profile, increased duration of sun exposure ⁴

Long-term real-world safety

German cohort study reporting a positive safety profile and ongoing clinical benefit ²⁰

Employment outcome, Dutch cohort

5% unemployed at baseline; none unemployed during treatment ¹¹

Health-technology assessment

NICE appraisal, 2023 ¹²

Drug-induced liver injury resource

Has a LiverTox entry ¹⁷

Mechanism

MC1R signalling: increased melanin synthesis, antioxidant activity, enhanced DNA repair, modulation of inflammation ⁷

Investigational uses

Vitiligo ¹⁵; broader dermatologic applications ⁹

What is sold as “Melanotan I”

Not the approved product; no established relationship to it

03 · Mechanism of action

A selective MC1R agonist, and selectivity is the point

Afamelanotide binds the melanocortin-1 receptor. MC1R signalling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation ⁷.

Four mechanisms, only one of which is pigmentation. The antioxidant and DNA-repair arms are why the compound is a photoprotective drug rather than a cosmetic, and MC1R selectivity is what separates it from the non-selective compound covered next in this family.

Why increased melanin helps in this specific disease

In erythropoietic protoporphyria, protoporphyrin IX accumulates and produces acute phototoxicity on light exposure ¹⁰. Eumelanin production, driven agonistically through MC1R ¹⁸, provides photoprotection that allows tolerated light exposure to increase.

The mechanism is matched to the pathology. That is what a properly developed drug looks like, and it is the reason the endpoint in the pivotal trial was duration of sun exposure rather than a pigmentation score.

Where the mechanism has been extended, and how far

The central melanocortin system is a broader drug target, and the 2019 approvals of afamelanotide and bremelanotide are cited as demonstrating the tractability of melanocortin receptors ¹³. Beyond protoporphyria, afamelanotide has been reviewed as an orphan drug with potential for broader dermatologic application ⁹, and appears among treatments reviewed for vitiligo ¹⁵ and in polymorphic light eruption ⁷.

Those are investigational. The reviews say so, and one explicitly calls for larger-scale studies ⁹.

04 · Key research findings

Early development, 2010–2015. Reviews of afamelanotide as an agonistic α-MSH analogue in the dermal phototoxicity of erythropoietic protoporphyria ¹, and of its application under the designation CUV1647 ³, setting out the genetics and existing therapy of the protoporphyrias and the pharmacological rationale.

The disease itself. A GeneReviews entry describes erythropoietic protoporphyria as characterised by cutaneous photosensitivity beginning in infancy or childhood, with tingling, burning, pain and itching within thirty minutes of sun or ultraviolet exposure ².

Worth stating plainly, because the severity of the indication is what justifies the regulatory pathway and the specialist-administered implant.

The pivotal trial, 2015. Published in the New England Journal of Medicine, with an international author list spanning porphyria centres in the United States, Europe and beyond. Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure ⁴.

This is among the highest-profile publications cited anywhere in this project, in a disease where the outcome measured is directly what patients lack.

Regulatory characterisation, 2016. A review describing afamelanotide as a synthetic α-MSH analogue and first-in-class MC1R agonist approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria ⁵, alongside a review of its role in the management of EPP and the phenotypically similar X-linked protoporphyria ⁶.

Pharmacokinetics and pharmacodynamics, 2017. A dedicated review of the compound’s PK/PD and clinical use in dermatologic disorders, setting out the four arms of MC1R signalling ⁷.

Very few compounds in this project have a published pharmacokinetic review. This one does, in a pharmacokinetics journal.

Clinical positioning, 2018–2021. Coverage within the non-acute porphyrias ⁸, a review of afamelanotide for prevention of phototoxicity in EPP ¹⁰, and an assessment of it as an orphan drug with potential for broader dermatologic applications, noting that larger-scale studies are needed ⁹.

Real-world outcomes in the Netherlands, 2023. A study of clinical features, psychosocial impact and the effect of afamelanotide, reporting that 5% of patients were unemployed at baseline and none were unemployed during treatment ¹¹.

An employment outcome is an unusual and unusually meaningful endpoint. It is also observational, and uncontrolled before-and-after comparisons in a progressive-management setting have obvious limitations — but it measures something no rating scale does.

Health-technology assessment and US uptake, 2023. A NICE appraisal of afamelanotide for treating erythropoietic protoporphyria ¹², and an account of the drug’s introduction and use in the United States ¹⁴.

A NICE appraisal means an independent body examined the cost-effectiveness case. Almost nothing else in this project has been assessed that way.

Patient perspective, 2024. A short published account from the patient side ¹⁶.

Liver safety documentation, 2024. An entry in LiverTox, the NIDDK clinical and research resource on drug-induced liver injury, describing afamelanotide as an MC1R agonist that stimulates melanin production and is used to decrease pain and itching from light exposure in erythropoietic protoporphyria and X-linked protoporphyria ¹⁷.

Inclusion in LiverTox is routine for approved drugs and is a form of systematic safety surveillance that unapproved compounds simply do not receive.

Vitamin D, 2024. A multicentre cohort study of cholecalciferol and afamelanotide effects on vitamin D levels in EPP, in patients whose lifelong photosensitivity has meant a lack of sunlight exposure ¹⁹.

A second-order clinical question — what happens to vitamin D status in a population that avoids the sun, and whether the drug changes it. The existence of this study is itself evidence of a mature clinical programme.

Long-term safety cohort, 2025. A German observational study of short- and long-term safety and clinical effectiveness of afamelanotide 16 mg in EPP, reporting a positive safety profile with ongoing clinical benefit ²⁰.

05 · Evidence overview

06 · Safety profile

Human data, from a regulated programme. The pivotal randomised trial reported an acceptable side-effect and adverse-event profile ⁴. A German observational cohort examining both short- and long-term use of the 16 mg implant reported a positive safety profile with ongoing clinical benefit ²⁰. The compound has a LiverTox entry, meaning it is covered by systematic drug-induced liver injury surveillance ¹⁷. Reviews of pharmacokinetics and pharmacodynamics ⁷ and of the drug in clinical use ^5,6,10 are available.

This is the most complete safety picture of any compound covered so far. It exists because the drug went through regulatory development, and it is the clearest available illustration of what that process produces that informal supply does not.

What is genuinely unknown, or outside the studied setting. Everything about use outside the approved population, form and supervision. The evidence concerns adults with erythropoietic protoporphyria receiving a 16 mg controlled-release implant in specialist care ²⁰. Nothing cited here establishes what the compound does in people without the disease, at other doses, by injection rather than implant, or without monitoring.

Two specific gaps. Cosmetic use is entirely unstudied in this file — no cited source examines administration for pigmentation in healthy people, and the approved endpoint is tolerated light exposure in a photosensitivity disorder, not appearance. And melanocortin agonism and pigmented lesions is a question this literature does not close: a drug that stimulates melanin production is one where dermatological monitoring is a reasonable expectation, and the sources cited here do not report long-term melanoma surveillance data.

Nothing is published on the identity, purity or content of any material sold as Melanotan I outside a pharmacy supply chain.

07 · US regulatory status

Current as of 7 September 2026. Afamelanotide was approved by the FDA in 2019 for erythropoietic protoporphyria-associated phototoxicity ¹³ and is marketed as SCENESSE. It is approved in the European Union for the prevention of phototoxicity in adults with erythropoietic protoporphyria ⁵ and has been in clinical use there since 2016 ¹⁸. NICE appraised it in 2023 ¹². It is a prescription medicine and is not a controlled substance.

This guide has not consulted the FDA or EMA approval records, labels or review documents, and states these approvals on the authority of the peer-reviewed sources cited. Indication wording, contraindications and warnings are matters for the label and are not reproduced or paraphrased here.

Material sold as “Melanotan I” outside a pharmacy is not the approved product.

Under the World Anti-Doping Code, afamelanotide does not appear as a named prohibited substance in the classes reviewed for this guide. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The entire evidence base concerns one rare disease. Erythropoietic protoporphyria and the related X-linked protoporphyria ^2,17. Results obtained in a population with a genetic photosensitivity disorder, using a specialist-administered implant, do not transfer to anyone else, and no cited source attempts that transfer.
2. There is no evidence here for cosmetic use. Not weak evidence — none. The approved endpoint is duration of tolerated sun exposure in people who cannot tolerate daylight ⁴.
3. Much of the real-world evidence is observational and uncontrolled. The Dutch employment finding ¹¹ and the German long-term cohort ²⁰ are cohort designs. They are valuable for safety and for capturing outcomes trials miss, and they cannot establish causation the way the randomised trial can.
4. The pivotal trial’s endpoint, while meaningful, is a behaviour. Duration of sun exposure ⁴ depends on patient choice as well as drug effect, and blinding is imperfect for a drug that visibly changes skin pigmentation. No cited source addresses how that was handled.
5. Long-term pigmented-lesion surveillance is not reported in the sources cited. For a drug whose action is stimulating melanin synthesis, this is a conspicuous gap in what was located, not a claim that such data do not exist elsewhere.
6. Investigational indications are exactly that. Vitiligo ¹⁵, polymorphic light eruption ⁷ and broader dermatologic uses ⁹ appear in reviews that call for larger studies.
7. The literature is concentrated among porphyria specialists and a small number of centres ^{1,3,4,6,10,11,19}, which is unavoidable in a rare disease and still limits independent replication.
8. No regulatory record was consulted, so approval details, restrictions and post-marketing requirements are outside this guide.
9. This guide has read abstracts, not full texts, including for the pivotal NEJM trial. Reported findings are those the abstracts state.
10. Nothing is known about material sold under the name Melanotan I. No published analysis has examined the identity or purity of any such product, and the gap matters more here than for an unapproved compound, because a regulated version exists that informal material is implicitly compared to.

09 · References

1. Minder EI. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin Investig Drugs. 2010 Dec;19(12):1591–1602. Review.

   PMID 21073357 ↗

2. Balwani M, Bloomer J, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Erythropoietic protoporphyria, autosomal recessive. In: GeneReviews. Seattle (WA): University of Washington; 2012 Sep 27, updated 2017 Sep 7.

   PMID 23016163 ↗

3. Minder EI, Schneider-Yin X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2015 Jan;8(1):43–53. Review.

   PMID 25470471 ↗

4. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015 Jul 2;373(1):48–59.

   PMID 26132941 ↗

5. Kim ES, Garnock-Jones KP. Afamelanotide: a review in erythropoietic protoporphyria. Am J Clin Dermatol. 2016 Apr;17(2):179–185. Review.

   PMID 26979527 ↗

6. Lane AM, McKay JT, Bonkovsky HL. Advances in the management of erythropoietic protoporphyria — role of afamelanotide. Appl Clin Genet. 2016 Dec 12;9:179–189. Review.

   PMID 28003770 ↗

7. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017 Aug;56(8):815–823. Review.

   PMID 28063031 ↗

8. Stölzel U, Kubisch I, Stauch T. [Porphyrias — what is verified?]. Internist (Berl). 2018 Dec;59(12):1239–1248. German. Review.

   PMID 30328490 ↗

9. Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2021 Feb;14(2):151–160. Review.

   PMID 33507118 ↗

10. Wu J, Cotliar R. Afamelanotide: an orphan drug with potential for broad dermatologic applications. J Drugs Dermatol. 2021 Mar 1;20(3):290–294. Review.

    PMID 33683075 ↗

11. Wensink D, Wagenmakers MAEM, Wilson JHP, Langendonk JG. Erythropoietic protoporphyria in the Netherlands: clinical features, psychosocial impact and the effect of afamelanotide. J Dermatol. 2023 Apr;50(4):445–452.

    PMID 36579412 ↗

12. Afamelanotide for treating erythropoietic protoporphyria. London: National Institute for Health and Care Excellence (NICE). 2023 Jul 26. No abstract available..

    PMID 40258105 ↗

13. Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. 2023 Sep;19(9):507–519. Review.

    PMID 37365323 ↗

14. Resnik SR, Targett D, Resnik BI. Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. J Drugs Dermatol. 2023 Sep 1;22(9):941–949.

    PMID 37683058 ↗

15. Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: pathogenesis and new and emerging treatments. Int J Mol Sci. 2023 Dec 9;24(24):17306. Review.

    PMID 38139134 ↗

16. O’Reilly M, McGuire VA, Dawe RS. Erythropoietic protoporphyria and afamelanotide: a patient’s perspective. Clin Exp Dermatol. 2024 Jan 25;49(2):186–187. No abstract available..

    PMID 37831089 ↗

17. Afamelanotide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2024 Mar 5.

    PMID 38598652 ↗

18. Polańska A, Wegner J, Nutbohm P, Staubach P, Żaba R, Dańczak-Pazdrowska A, Jenerowicz D. Afamelanotide in protoporphyria and other skin diseases: a review. Postepy Dermatol Alergol. 2024 Apr;41(2):149–154. Review.

    PMID 38784937 ↗

19. Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, Kuerten V, Schelonke K, Homey B, Langendonk JG. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. Br J Dermatol. 2024 Aug 14;191(3):357–364.

    PMID 38634774 ↗

20. Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P. German cohort observational study to investigate the short- and long-term safety and clinical effectiveness of afamelanotide 16 mg (SCENESSE) in patients with erythropoietic protoporphyria (EPP). Photodermatol Photoimmunol Photomed. 2025 Mar;41(2):e13012.

    PMID 40082741 ↗